Luzindole

Research use only, not for human use.

Luzindole is a selective melatonin receptor antagonist.

Luzindole is a selective melatonin receptor antagonist. Luzindole inhibits experimental autoimmune encephalomyelitis and exerts antidepressant-like activity. Luzindole preferentially targets MT2 (Mel1b) over MT1 (Mel1a) with Ki values of 10.2 and 158 nM for human MT2 and MT1, respectively.

Luzindole (N-0774) (5-10 μg/ml) inhibits antigen-specific proliferation of the MBP-reactive LV-4 T cell line.

Luzindole (N-0774) (30 mg/kg; i.p.; days 0-5) suppresses experimental autoimmune encephalomyelitis.Luzindole (N-0774) (30 mg/kg i.p.) reduces the time of immobility in a dose-dependent manner, the effect being more pronounced at midnight (60% reduction) than at noon (39% reduction). The effect of luzindole is time-dependent, showing a maximal effect at 60 min. The anti-immobility effect of luzindole (10 mg/kg i.p.) is prevented by the administration of melatonin (30 mg/kg i.p.). Luzindole (30 mg/kg i.p.) did not modify the time of immobility either at noon or midnight in the albino ND/4 mouse, or in the C57BL/6J mouse, which does not produce melatonin. Animal Model:Twenty-three- to 12-week-old(SJL X PL/J ) F1 mice Dosage:30 mg/kg Administration:i.p.; days 0-5 (between 23: 00 and 1: 00 under conditions of minimal lighting)Result:Effectively prevented experimental autoimmune encephalomyelitis.

N-0774

Others

Other Targets

MT1 receptor|MT2 receptor

——

——

117946-91-5

292.37

C19H20N2O

>98% (HPLC)

DMSO:100 mg/mL (342.03 mM; Need ultrasonic)

CC(NCCc1c(Cc2ccccc2)[nH]c2c1cccc2)=O

——

(-20℃)

With Ice Pack

≥ 2 years